A Weak Neutralizing Antibody Response to Hepatitis C Virus Envelope Glycoprotein Enhances Virus Infection

We have completed a phase 1 safety and immunogenicity trial with hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, with MF59 adjuvant as a candidate vaccine. Neutralizing activity to HCV genotype 1a was detected in approximately 25% of the vaccinee sera. In this study, we evaluated vaccinee...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Keith, Banerjee, Arup, Frey, Sharon E., Belshe, Robert B., Ray, Ranjit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161815/
https://www.ncbi.nlm.nih.gov/pubmed/21887300
http://dx.doi.org/10.1371/journal.pone.0023699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161815/
https://www.ncbi.nlm.nih.gov/pubmed/21887300
http://dx.doi.org/10.1371/journal.pone.0023699

Ejemplares similares